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Association of Patient Out-of-Pocket Costs With Prescription
Abandonment and Delay in Fills of Novel Oral Anticancer Agents
Abstract
High out-of-pocket (OOP) costs may limit access to novel oral cancer medications. In a retrospective study,
nearly one third of patients whose OOP costs were $100 to $500 and nearly half of patients whose OOP costs
were more than $2,000 failed to pick up their new prescription for an oral cancer medication, compared to
10% of patients who were required to pay less than $10 at the time of purchase. Delays in picking up
prescriptions were also more frequent among patients facing higher OOP costs.
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THE QUESTION
The number of novel oral anticancer therapies has increased considerably 
in recent years, often accompanied by a high price tag. Due to an increase 
in high-deductible health plans and growing use of specialty tiers with 
coinsurance (as opposed to fixed copayment) requirements, many cancer 
patients face high out-of-pocket (OOP) costs for these medications. Because 
patients must pay the entire OOP cost for an oral prescription up front, these 
costs present a unique risk that patients will delay pick-up of the prescription or 
opt not to fill it at all.  
To better understand how these costs affect the initiation of novel treatments, 
the authors analyzed claims data for patients covered by commercial insurance 
or Medicare Part D who received a new prescription for any of 38 oral 
anticancer medications from 2014-2015. These claims data were unique in that 
they included all prescriptions approved by the payer, including those that the 
patient opted not to fill, along with the amount due from the patient at the 
time of pickup after coupons or copayment assistance were applied.
THE FINDINGS
Among 38,111 patients, the average OOP cost was $486; overall, 18% of 
patients “abandoned” their index prescription, meaning that they did not 
pick up an insurer-approved prescription for the index medication within 90 
days. On average, patients who abandoned their prescription had higher 
mean OOP costs ($1,397) than those who filled it ($284). Across OOP cost 
categories, few patients who abandoned their prescription went on to have 
prescription claims for alternate cancer treatments, including intravenous 
therapies, in the following 90 days. 
Adjusting for socioeconomic and clinical characteristics, the authors found 
that rates of abandonment and delay increased as the OOP cost category 
increased, in a linear fashion. As shown in Figure 1, nearly half of patients 
(49%) facing OOP costs over $2,000 abandoned their prescription, whereas 
only 10% of patients facing OOP costs of less than $10 did.  Among patients 
in the lowest OOP cost category, only 3% delayed filling their prescription, 
compared with 18% in the highest OOP cost category. The average delay 
was 35 days, which was similar across all OOP cost categories. 
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These patterns were consistent across cancers. Although abandonment rates 
were highest for medications to treat metastatic cancers that typically have 
poorer prognosis, a substantial percentage of patients abandoned treatment 
even for cancers where the medication has been shown to extend life by 
many years.
The authors used these risk-adjusted rates to simulate how abandonment 
might change in light of ongoing trends toward higher OOP costs. This 
simulation revealed that if patients currently responsible for $50 to $100 per 
prescription were shifted to the next higher OOP cost category ($100 to 
$500), abandonment rates would likely double (from 16% to 36%).
THE IMPLICATIONS
This study raises questions about whether patients will be able to take 
advantage of new cancer treatments. Currently, OOP costs greater than 
$2,000 for a new oral cancer medication are typical for Medicare Part D 
patients without low-income subsidies and for many commercially insured 
patients. Given the study’s focus on new treatment episodes, these findings 
suggest that financial barriers may limit patient access to what may be the 
provider’s and/or patient’s first choice medication. Such obstacles may  
impose additional financial burdens and inflict emotional stress at a time  
when patients are already coping with a life-altering diagnosis or change in 
medical status.
The findings also point to the need for timely patient-provider conversations 
to evaluate any alternate, lower OOP cost treatment options. This is 
especially important with self-administered treatments, where initiation delay 
and nonadherence are more difficult to monitor. As the availability of oral 
anticancer treatment options continues to increase, access and affordability 
will determine the true benefit for patients. All stakeholders – including 
manufacturers, pharmacy benefit managers, payers, and policymakers – must 
work to identify fiscally sustainable strategies to improve patient access to 
cancer medications.
THE STUDY
This retrospective, claims-based analysis used data from a large, proprietary, 
integrated database that includes point-of-sale prescription purchase 
information detailing the patient’s OOP liability (after application of coupons 
or copay assistance) and final claim payment status (paid or reversed claim). 
The final sample included 38,111 patients with a new, payer-approved 
prescription for any of 38 oral anticancer medications between 2014-2015. 
The authors tracked whether patients filled their prescription after it was 
approved by the insurer, and if not (i.e., the claim was reversed), whether 
the prescription was filled with a delay (within 90 days) or abandoned 
completely. The authors also examined whether patients who abandoned 
their prescription initiated alternate treatment from the same drug class, 
including intravenous therapies, in the following 90 days. They adjusted for 
other relevant factors, including type of insurance, type of pharmacy, and 
patient characteristics, and explored differences for several patient subgroups 
(by insurance coverage, pharmacy type, sex, and indication).
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FIGURE 1. 
PRESCRIPTION ABANDONMENT AND DELAY IN FILLS OF 
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